Sanofi Bids €308m To Buy Kiadis
Premium of 272%
Executive Summary
Arthur Lahr, CEO of the Dutch biotech, said the offer is testimony to the uniqueness of the firm's natural killer (NK) cell platform "and the rapid success of Kiadis’s transformation."
You may also be interested in...
J&J-Bound Reed Reaches End Of The Road As Sanofi R&D Chief
The French drugmaker has begun an external and internal search to succeed John Reed who is heading for Johnson & Johnson after an up-and-down five years as Sanofi’s R&D chief.
Sanofi ThiNKs Scribe’s CRISPR Approach Can Advance Its NK Cell Therapy Goals
Deal Snapshot: CRISPR-Cas9 co-inventor Jennifer Doudna-founded gene-editing firm inks its second large collaboration, teaming with Sanofi on off-the-shelf natural killer cell therapies for cancer.
Sanofi Exit From Sickle Cell Gene Therapy Leaves Sangamo With Difficult Decision
Sanofi’s decision is influenced by its own in-house options, but also by the growing competition in sickle cell gene therapy.